Bioventus Inc. (BVS) vs Odyssey Therapeutics, Inc. (ODTX)
A side-by-side comparison of Bioventus Inc. and Odyssey Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BVS
Bioventus Inc.
$13.10HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ODTX
Odyssey Therapeutics, Inc.
$18.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BVS vs ODTX
growth of $100 · dividends reinvested · last 1yBVS +26.9% (+26.9%/yr)ODTX +26.9% (+26.9%/yr)BVS compounded faster over this window
BVS ODTX
BVS vs ODTX: by the numbers
- •BVS is the larger company ($887M vs $871M market cap).
- •BVS is profitable (9.36% net margin) while ODTX runs a net loss (-4994.86%).
Metrics side by side
Valuation
| Metric | BVS | ODTX |
|---|---|---|
| P/E ratio | 17.01 | N/A |
| Forward P/E | 16.82 | N/A |
| P/S ratio | 1.53 | N/A |
| P/B ratio | 3.89 | 2.07 |
| EV / EBITDA | 10.48 | N/A |
| FCF yield | 10.62% | N/A |
Profitability
| Metric | BVS | ODTX |
|---|---|---|
| Gross margin | 68.00% | 100.00% |
| Operating margin | 10.63% | -5415.19% |
| Net margin | 9.36% | -4994.86% |
| ROE | 23.86% | N/A |
| ROIC | 11.37% | -66.23% |
Growth (annualized)
| Metric | BVS | ODTX |
|---|---|---|
| Revenue CAGR (5Y) | 11.82% | N/A |
| EPS CAGR (5Y) | -5.03% | N/A |
| FCF CAGR (5Y) | 43.36% | N/A |
| Total return CAGR (5Y) | -0.81% | N/A |
Frequently asked
- Is BVS or ODTX more profitable?
- BVS runs the higher net margin — BVS at 9.36% versus ODTX at -4994.86%.
Go deeper
Dig into the metrics
Bioventus P/E ratioBioventus ROEOdyssey Therapeutics ROEBioventus operating marginOdyssey Therapeutics operating marginBioventus revenue growthOdyssey Therapeutics revenue growthBioventus free cash flowOdyssey Therapeutics free cash flow
Bioventus & Odyssey Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.